PCOS vs PMOS: What Changed When the Name Did

What is the actual difference between PCOS and PMOS?

The words. That is the whole difference.

Polycystic ovary syndrome and polyendocrine metabolic ovarian syndrome describe one condition, diagnosed the same way, treated the same way, affecting one in eight women. In a consensus published in The Lancet in 2026, 56 academic, clinical and patient organisations agreed to retire the old name and adopt the new one.

If you were diagnosed with PCOS in 2019, you have PMOS. You do not have a new condition, a different condition, or a condition that needs re-confirming.

Why was the name changed at all?

Because the old one described a feature that is not really there.

The “cysts” on a polycystic ovary are not cysts. They are ordinary immature follicles, visible in larger numbers than average on an ultrasound — not pathological growths, not something that needs removing. The consensus paper is direct about it: the term PCOS “is inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features.”

That mismatch has been measurable for over a decade. In a 2014 Australian survey of 57 women with PCOS and 105 primary care physicians, 47% of the women incorrectly named ovarian cysts as a key feature of the condition, 48% found the name confusing and 51% wanted it changed. Among the physicians, 74% agreed the name was confusing and 81% said it needed changing. It is a small, self-selected sample — but the direction was clear enough to trigger twelve years of work.

The new name swaps in three words the group judged more accurate. Polyendocrine for the multiple hormone systems involved. Metabolic for the insulin and cardiometabolic features that the old name hid entirely. Ovarian because the ovary is still central. The full history of how those words were chosen is in why PCOS was renamed.

PCOS vs PMOS, line by line

Item	Under PCOS	Under PMOS	Changed?
Full name	Polycystic ovary syndrome	Polyendocrine metabolic ovarian syndrome	Yes
Acronym	PCOS	PMOS — keeping the old acronym was considered and rejected	Yes
The underlying condition	Same	Same	No
Diagnostic criteria	2 of 3 Rotterdam features	2 of 3 Rotterdam features	No
Phenotypes	Four (A–D)	Four (A–D)	No
Treatment options	Unchanged	Unchanged	No
A diagnosis you already have	Valid	Valid — no retesting	No
Disease classification codes	Coded as PCOS	Alignment with health systems and classification is under way	In progress
Published research	Indexed as PCOS	New papers will use PMOS; the back catalogue stays PCOS	Partly

What did not change: how it is diagnosed

The rename consensus is a paper about a name. It does not revise a single diagnostic threshold.

The criteria still in force come from the 2023 International Evidence-based Guideline — 254 recommendations and practice points, developed with 39 professional and consumer organisations across 71 countries. Diagnosis still requires two of these three:

1. Irregular or absent ovulation — cycles that are too long, too short, or missing.
2. Hyperandrogenism — either clinically (hirsutism, acne, scalp hair loss) or on bloods.
3. Polycystic ovarian morphology on ultrasound, or, in adults only, a raised anti-Müllerian hormone (AMH) level as an alternative to the scan.

Other causes have to be excluded first. Ultrasound is still not used to diagnose anyone within eight years of their first period. That third criterion is the one carrying the word “cystic” — and it is worth knowing that it is the optional one. Plenty of people meet criteria one and two and have never had an abnormal scan. The detail sits in the PMOS diagnostic criteria.

Does the new name apply the same way to every phenotype?

The name is the same for everyone. The word “metabolic” inside it does not weigh the same for everyone.

The four phenotypes are built from those three criteria in different combinations, and they do not carry identical metabolic risk. In a 2013 position paper, Dunaif and Fauser argued that the phenotypes defined by hyperandrogenism plus anovulation identify the highest metabolic risk, while the extra phenotypes added by the Rotterdam criteria are more reproductive than metabolic. They proposed splitting the condition into two names on exactly that basis.

The 2026 consensus went the other way and chose one name for all four. That is a reasonable call for a single label — but it means the “metabolic” in PMOS is a description of the syndrome as a category, not a prediction about you personally. If you are the non-hyperandrogenic phenotype, your metabolic workup still matters; it just may not be the loudest part of your picture.

Which phenotype you fit is the question that actually changes what you do next. Start with the four types.

Will the new name fix delayed diagnosis?

Nobody knows yet, and it would be dishonest to say otherwise.

The problem is real and well documented. In a 2017 survey of 1,385 women with a reported PCOS diagnosis, 33.6% said it took more than two years to get diagnosed, 47.1% saw three or more health professionals first, and only 15.6% were satisfied with the information they received at diagnosis. That study recruited through support-group websites, so the sample skews toward people who went looking for help — but 1,385 people is not a rounding error.

The consensus argues the old name contributed to that pattern by pointing clinicians at the ovary and away from the endocrine and metabolic picture. That is a plausible mechanism. It is not yet a measured outcome. A name change on its own does not shorten a waiting list, and the paper pairs it with an implementation strategy — education, transition period, classification alignment — precisely because the word alone was never going to do the work.

Which word should you use, and where?

Both are correct right now. The consensus deliberately chose “evolution rather than transformation”, with a transition period. Here is the practical version.

Where	Expect to see	What to do
Your GP or specialist	Either — PCOS is still what most notes say	Say both once: “PCOS, now called PMOS.” Then use whichever they use.
Existing medical records	PCOS	Nothing. No correction is needed and none is owed.
Billing and insurance codes	PCOS	Nothing — classification alignment is being handled centrally.
Lab and imaging requests	PCOS	Nothing. No test changed.
Searching PubMed	Almost everything is indexed as PCOS	Search “polycystic ovary syndrome” for anything published before mid-2026.
Clinical guidelines	The 2023 guideline says PCOS	Still the current guideline. The name on it does not date it.
Support groups and charities	Both, shifting to PMOS	Either. Many of these organisations co-authored the change.

What this does not change

Worth saying plainly, because renames invite hope they cannot carry.

• Not a new treatment. Metformin, combined hormonal contraception, letrozole, inositol, and lifestyle measures are unaffected by what the condition is called.
• Not a new prognosis. Your metabolic and cardiovascular risk profile is what it was in April 2026.
• Not a reclassification. You have not been moved into a different category or phenotype.
• Not a reason to redo anything. No repeat scan, no repeat bloods, no new referral.

The condition, the biology and the management are all where they were. Only the name moved.

Your next step

Do one thing: write both names on the top of the notes you take into your next appointment — “PCOS (PMOS)” — and use that line once, at the start, so you and the clinician are provably talking about the same thing.

Then work out which phenotype you fit, because that is the question that changes what you actually do. How to raise the name change with your doctor covers the awkward version of that conversation, and the rest of the diagnosis section assumes you know your type.